Blueprint Medicines Corporation (NASDAQ:BPMC) will be issuing its quarterly earnings data before the market opens on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($0.79) per share for the quarter.
Blueprint Medicines Corporation (NASDAQ:BPMC) last released its earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by $0.11. The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $6.02 million. Blueprint Medicines Corporation had a negative return on equity of 55.58% and a negative net margin of 317.57%. The business’s revenue for the quarter was down 14.9% compared to the same quarter last year. During the same period last year, the company posted ($0.57) earnings per share. On average, analysts expect Blueprint Medicines Corporation to post $-3.24 EPS for the current fiscal year and $-3.87 EPS for the next fiscal year.
Shares of Blueprint Medicines Corporation (NASDAQ BPMC) opened at 53.07 on Monday. Blueprint Medicines Corporation has a 12-month low of $20.62 and a 12-month high of $56.81. The stock’s 50 day moving average price is $49.38 and its 200 day moving average price is $41.46. The firm’s market capitalization is $1.76 billion.
Several equities analysts have recently weighed in on BPMC shares. Canaccord Genuity set a $52.00 price target on Blueprint Medicines Corporation and gave the company a “buy” rating in a research report on Tuesday, June 6th. TheStreet cut Blueprint Medicines Corporation from a “c-” rating to a “d+” rating in a research report on Wednesday, May 3rd. Jefferies Group LLC lifted their price target on Blueprint Medicines Corporation from $42.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, May 4th. Wedbush reiterated an “outperform” rating and issued a $55.00 price target on shares of Blueprint Medicines Corporation in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded Blueprint Medicines Corporation from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 27th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $47.40.
In related news, insider Kate Haviland sold 6,357 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $50.00, for a total transaction of $317,850.00. Following the completion of the transaction, the insider now directly owns 6,357 shares in the company, valued at $317,850. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Daniel Lynch sold 7,500 shares of the business’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $55.06, for a total value of $412,950.00. Following the transaction, the director now owns 211,842 shares of the company’s stock, valued at $11,664,020.52. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 73,622 shares of company stock valued at $3,771,405. 3.40% of the stock is owned by company insiders.
Blueprint Medicines Corporation Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
